Vaxcyte (PCVX) EBIT (2019 - 2026)
Vaxcyte (PCVX) posted quarterly EBIT of -$345.8 million for Q1 2026, down 91.3% year-over-year from -$4.0 billion in Q1 2025, and down 26.09% quarter-over-quarter from -$274.3 million in Q4 2025.
Vaxcyte (PCVX) EBIT (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported EBIT for 8 consecutive years, with -$345.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT fell 91.3% year-over-year to -$345.8 million; the TTM figure through Mar 2026 stood at -$1.1 billion (down 71.22% YoY), while the FY2025 annual figure was -$923.7 million, down 62.18% from the prior year.
- EBIT eased to -$345.8 million in Q1 2026 per PCVX's latest filing, from -$274.3 million in the prior quarter.
- Across five years, EBIT topped out at -$39.2 million in Q1 2022 and bottomed at -$345.8 million in Q1 2026.
- Historically, EBIT has averaged -$149.4 million across 5 years, with a median of -$139.9 million in 2024.
- Annual changes were most pronounced in 2022 — EBIT plunged 190.07% — and 2024, when it advanced 17.55%.
- Vaxcyte's EBIT stood at -$86.6 million in 2022, then plunged by 127.18% to -$196.7 million in 2023, then rose by 17.55% to -$162.2 million in 2024, then plunged by 69.13% to -$274.3 million in 2025, then declined by 26.09% to -$345.8 million in 2026.
- Business Quant data shows PCVX's EBIT at -$345.8 million in Q1 2026, -$274.3 million in Q4 2025, and -$242.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | -302.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -302.78 Mn |
| Mar 31, 2026 | -345.85 Mn |
| Dec 31, 2025 | -274.28 Mn |
| Sep 30, 2025 | -242.38 Mn |
| Jun 30, 2025 | -226.22 Mn |
| Mar 31, 2025 | -180.79 Mn |
| Dec 31, 2024 | -162.17 Mn |
| Sep 30, 2024 | -139.92 Mn |
| Jun 30, 2024 | -152.98 Mn |
| Mar 31, 2024 | -114.47 Mn |
| Dec 31, 2023 | -196.68 Mn |
| Sep 30, 2023 | -113.03 Mn |
| Jun 30, 2023 | -87.15 Mn |
| Mar 31, 2023 | -71.19 Mn |
| Dec 31, 2022 | -86.57 Mn |
| Sep 30, 2022 | -58.58 Mn |
| Jun 30, 2022 | -47.89 Mn |
| Mar 31, 2022 | -39.22 Mn |
| Dec 31, 2021 | -29.85 Mn |
| Sep 30, 2021 | -26.95 Mn |